NASDAQ:IFRX - Inflarx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $33.18 +2.02 (+6.48 %) (As of 02/17/2019 04:00 PM ET)Previous Close$33.18Today's Range$30.9741 - $34.127552-Week Range$20.31 - $42.83Volume91,053 shsAverage Volume67,000 shsMarket Capitalization$776.74 millionP/E Ratio-11.29Dividend YieldN/ABeta-0.94 ProfileDiscussionAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Receive IFRX News and Ratings via Email Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IFRX Previous Symbol CUSIPN/A Webwww.inflarx.de Phone49-36-4150-8180Debt Debt-to-Equity RatioN/A Current Ratio18.71 Quick Ratio18.71Price-To-Earnings Trailing P/E Ratio-11.29 Forward P/E Ratio-24.95 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.77 per share Price / Book5.75Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees21 Outstanding Shares23,410,000Market Cap$776.74 million OptionableNot Optionable Inflarx (NASDAQ:IFRX) Frequently Asked Questions What is Inflarx's stock symbol? Inflarx trades on the NASDAQ under the ticker symbol "IFRX." How were Inflarx's earnings last quarter? Inflarx NV (NASDAQ:IFRX) announced its earnings results on Wednesday, November, 21st. The company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.10. View Inflarx's Earnings History. When is Inflarx's next earnings date? Inflarx is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Inflarx. What price target have analysts set for IFRX? 7 brokerages have issued 12-month price objectives for Inflarx's shares. Their forecasts range from $42.00 to $65.00. On average, they anticipate Inflarx's share price to reach $51.4286 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price. View Analyst Price Targets for Inflarx. What is the consensus analysts' recommendation for Inflarx? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inflarx. Has Inflarx been receiving favorable news coverage? News articles about IFRX stock have been trending somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Inflarx earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. Who are some of Inflarx's key competitors? Some companies that are related to Inflarx include Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), Akcea Therapeutics (AKCA), Endo International (ENDP), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Insmed (INSM), Madrigal Pharmaceuticals (MDGL), Portola Pharmaceuticals (PTLA) and Xencor (XNCR). Who are Inflarx's key executives? Inflarx's management team includes the folowing people: Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)Mr. Arnd Christ, Chief Financial Officer (Age 53)Jason Marks, Chief Legal Officer/Gen. CounselMr. Jordan Silverstein, Head of Corp. Devel. & Strategy When did Inflarx IPO? (IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Inflarx's major shareholders? Inflarx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (8.91%), BlackRock Inc. (5.39%), Polar Capital LLP (0.61%), Emory University (0.35%), Millennium Management LLC (0.31%) and Essex Investment Management Co. LLC (0.09%). Which institutional investors are selling Inflarx stock? IFRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp, Emory University and D. E. Shaw & Co. Inc.. Which institutional investors are buying Inflarx stock? IFRX stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Polar Capital LLP, Essex Investment Management Co. LLC, Bank of America Corp DE, Paloma Partners Management Co and Millennium Management LLC. How do I buy shares of Inflarx? Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Inflarx's stock price today? One share of IFRX stock can currently be purchased for approximately $33.18. How big of a company is Inflarx? Inflarx has a market capitalization of $776.74 million. The company earns $-27,390,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Inflarx employs 21 workers across the globe. What is Inflarx's official website? The official website for Inflarx is http://www.inflarx.de. How can I contact Inflarx? Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180. MarketBeat Community Rating for Inflarx (NASDAQ IFRX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 103 (Vote Outperform)Underperform Votes: 121 (Vote Underperform)Total Votes: 224MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: What is the NASDAQ Stock Market?